Skip to content

Axsome Therapeutics

US · AXSM #1533 by market cap Listed 2015
129.36 -6.32 -4.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
D-
Momentum strategy signal
Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Mixed
1
■ Upgrades■ Downgrades
  • 0 upgrades vs 1 downgrade among tracked analyst rating changes.
  • Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.

Analyst consensus 17 analysts

Buy
Avg price target 263.94 +104.0%
Price target rangecurrent 129.36
Low220.00
Avg263.94
High310.00
Buy 94% Hold 6% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-13 Morgan Stanley -- Hold 223.00
2026-11-09 H.C. Wainwright -- Buy 290.00
2026-11-04 Mizuho Securities -- Buy 272.00
2026-11-03 Wells Fargo -- Buy 256.00
2026-11-03 UBS -- Buy 239.00
2026-11-03 Baird -- Buy 220.00
2026-11-03 Morgan Stanley -- Hold 249.00
2026-11-03 Deutsche Bank -- Buy 245.00
2026-11-03 Guggenheim -- Buy 250.00
2026-11-02 Cantor Fitzgerald -- Buy 272.00
2026-11-02 UBS -- Buy 239.00
2026-11-02 Piper Sandler -- Buy 235.00
2026-11-02 BofA Securities -- Buy 264.00
2026-11-02 Morgan Stanley -- Hold 249.00
2026-11-02 Jefferies -- Buy 305.00
2026-11-02 BMO Capital -- Buy 310.00
2026-11-02 RBC Capital -- Buy 273.00
2026-10-29 Mizuho Securities -- Buy 284.00
2026-10-29 Oppenheimer -- Buy 280.00
2026-10-26 Piper Sandler -- Buy 238.00
2026-10-15 Needham -- Buy 268.00
2026-10-14 RBC Capital -- Buy 295.00
2026-10-12 BMO Capital -- Buy 310.00
2026-10-09 BofA Securities -- Buy 276.00
2026-10-08 RBC Capital -- Buy 295.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-01-08 Morgan Stanley Buy → Hold 204.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-02 -- ±13.38% -5.83% (in line)
2026/Q2 2026-08-10 -- ±8.79% +3.83% (in line)
2026/Q1 2026-05-04 -- ±5.99% +8.31% (beat)
2025/Q4 2026-02-23 -- ±7.60% -4.88% (in line)
2025/Q3 2025-11-03 -- ±7.47% +0.56% (in line)
2025/Q2 2025-08-04 -- ±8.91% +3.42% (in line)
2025/Q1 2025-05-05 -- ±9.42% +3.81% (in line)
2024/Q4 2025-02-18 -- ±7.68% -2.33% (in line)
2024/Q3 2024-11-12 -- ±9.77% +9.35% (in line)
2024/Q2 2024-08-05 -- ±11.19% -1.43% (in line)
2024/Q1 2024-05-06 -- ±9.37% +1.52% (in line)
2023/Q4 2024-02-20 -- ±12.67% -12.57% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Axsome Therapeutics discussion 0 comments

Add a comment